The role of Trastuzumab in patients with gastric cancer

Trastuzumab (Trastuzumab) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with breast cancer or metastatic gastric cancer (gastric or gastroesophageal junction adenocarcinoma) whose tumors overexpress the HER2 gene (HER2+). Trastuzumab combined with chemotherapy has been shown to prolong the survival of patients with HER2-positive advanced gastric cancer. Research shows that combining trastuzumab with chemotherapy significantly improves overall survival compared to chemotherapy alone.

Trastuzumab combined with chemotherapy can also reduce the risk of tumor progression in patients with HER2-positive gastric cancer. This means that trastuzumab can help control the growth and spread of tumors, thereby delaying the progression of the disease. Trastuzumab can increase the response rate of HER2-positive gastric cancer patients to chemotherapy, which means that trastuzumab can improve the sensitivity of gastric cancer patients to chemotherapy drugs and enhance the therapeutic effect. In the setting of metastatic gastric cancer, the most common adverse reactions with trastuzumab compared with chemotherapy alone were neutropenia, diarrhea, fatigue, anemia, stomatitis, weight loss, upper respiratory tract infection, pyrexia, thrombocytopenia, mucosal inflammation, nasopharyngitis, and dysgeusia.

Trastuzumab is sold under the brand name Herceptin in China and has entered the scope of Class B medical insurance, but it may be limited to patients who meet the indications for this drug, such as patients with HER2-positive metastatic breast cancer and its adjuvant and neoadjuvant treatment or HER2-positive metastatic gastric cancer. The price is around 6,000 yuan. The original trastuzumab drug has also been launched overseas. The drug ingredients of domestic and foreign original drugs are basically the same. For specific prices and drug details, you can consult the medical consultant. There is currently no generic drug of trastuzumab on the market.